Partial Response Reported With Abemaciclib for Breast Cancer Metastases to Brain

Trastuzumab Does Not Benefit HER2-Low Breast Cancer Patients

Trastuzumab Does Not Benefit HER2-Low Breast Cancer Patients

Last Updated: December 06, 2017. The results were presented at the San Antonio Breast Cancer Symposium.

The PANACEA study is an worldwide Phase Ib/II study that was created to evaluate the safety and efficacy of using immunotherapy with pembrolizumab in combination with the standard therapy trastuzumab in patients with HER2-positive metastatic breast cancer.

Debu Tripathy, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues reported the results from a randomized phase III trial assessing ribociclib + tamoxifen/non-steroidal aromatase inhibitor and goserelin in pre- and peri-menopausal women.

Preliminary estimates of median progression-free survival have reached 10.4 months. Consistent PFS benefits were seen for ribociclib versus placebo in subgroup analyses. For example, the overall response rate, which is the percentage of patients who had a partial or a complete response, was significantly higher among patients with measurable disease at baseline in the ribociclib arm compared with the placebo arm (51% vs. 36%).

"Longer follow-up is needed to determine whether the trial will meet its secondary end point of overall survival", Tripathy said in a statement.

"The results of the PANACEA study are very encouraging", stated Dr Sherene Loi, PhD, associate professor at Peter MacCallum Cancer Centre in Melbourne, Australia, who works with the International Breast Cancer Study Group (IBCSG).

One author disclosed financial ties to Novartis, which manufactures ribociclib and funded the study.